News
- Author:
-
Mark S. Lesney, PhD
Publish date: May 18, 2021
Pegcetacoplan (Empaveli) was approved as a treatment for paroxysmal nocturnal hemoglobinuria (PNH).
News
- Author:
-
Mark S. Lesney, PhD
Publish date: April 22, 2021
Among t-AML patients who underwent HSCT, a significant decrease in survival was associated with an increasing...
News
- Author:
-
Kate O’Rourke
Publish date: April 21, 2021
Ublituximab plus ibrutinib was superior to ibrutinib alone for patients with relapsed or refractory high-risk...
News
- Author:
-
Pam Harrison
Publish date: April 14, 2021
Nearly half did not produce antibodies even though they had all received both doses of one of the new mRNA COVID...
News
- Author:
-
Sharon Worcester
Publish date: April 8, 2021
Palliative care improved several outcome measures and should be used early and often in patients with...
News
- Author:
-
Jeff Evans
-
Bruce Jancin
Publish date: April 7, 2021
VEXAS is a novel adult-onset autoinflammatory syndrome in older men and is often associated with hematologic...
News
- Author:
-
Kerry Dooley Young
Publish date: March 18, 2021
The FDA is conducting a review of therapies granted accelerated approval for cancer indications.
News
- Author:
-
Mark S. Lesney, PhD
Publish date: March 17, 2021
Conventional chemotherapy plus rituximab (R-CHOEP-14) was compared to high-dose chemotherapy plus rituximab...
Conference Coverage
- Author:
-
Neil Osterweil
Publish date: March 9, 2021
Despite girls having abnormally heavy menstrual bleeding, their families and physicians may not recognize signs...
News
- Author:
-
Roxanne Nelson, RN, BSN
Publish date: March 4, 2021
The response rate was 73% in a patient population with a median of six lines of therapy, with one-third of...
Pages
